NASDAQ:THTX Theratechnologies Q2 2025 Earnings Report $3.30 +0.02 (+0.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.30 0.00 (-0.15%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Theratechnologies EPS ResultsActual EPS-$0.09Consensus EPS -$0.01Beat/MissMissed by -$0.08One Year Ago EPSN/ATheratechnologies Revenue ResultsActual Revenue$17.73 millionExpected Revenue$24.30 millionBeat/MissMissed by -$6.57 millionYoY Revenue GrowthN/ATheratechnologies Announcement DetailsQuarterQ2 2025Date7/9/2025TimeBefore Market OpensConference Call DateWednesday, July 9, 2025Conference Call Time8:30AM ETUpcoming EarningsTheratechnologies' Q3 2025 earnings is scheduled for Thursday, October 9, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Theratechnologies Earnings HeadlinesTheratechnologies shareholders approve proposed acquisition by Future PakSeptember 12 at 3:19 PM | msn.comTheratechnologies Shareholders Approve Acquisition by Future Pak AffiliateSeptember 12 at 12:10 PM | tipranks.comCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took dozens of technology and finance experts, including one PhD astrophysicist, and $4 million in total research costs). In a multi-year backtest, this breakthrough beat stocks, bonds, gold... even Warren Buffett.September 14 at 2:00 AM | Stansberry Research (Ad)Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12 at 11:31 AM | financialpost.comFTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12 at 11:23 AM | globenewswire.comTheratechnologies announces availability of EGRIFTA WRSeptember 6, 2025 | msn.comSee More Theratechnologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theratechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theratechnologies and other key companies, straight to your email. Email Address About TheratechnologiesTheratechnologies (NASDAQ:THTX) is a Canadian biopharmaceutical company focused on discovering, developing and commercializing innovative therapies to address metabolic and endocrine disorders. Headquartered in Montréal, Quebec, the company leverages its expertise in peptide-based molecules to target conditions with significant unmet medical needs, including those associated with aging, HIV-related lipodystrophy and non-alcoholic fatty liver disease (NAFLD). The company’s lead commercial product is Egrifta® (tesamorelin), a synthetic growth hormone-releasing factor analogue approved in the United States and Canada for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta marked the first regulatory approval of a therapy specifically indicated for this condition, and it continues to generate royalty and product sales through direct marketing in North America under Theratechnologies’ own commercialization infrastructure. Beyond its marketed therapy, Theratechnologies maintains an active R&D pipeline aimed at expanding the use of tesamorelin into additional metabolic indications such as NAFLD, as well as pursuing novel peptide candidates in preclinical and early-stage clinical development. The company has entered licensing and collaboration agreements with partners in North America, Europe and Asia to facilitate late-stage trials and potential regulatory filings in new markets. Founded in 1993, Theratechnologies is governed by a board of directors and led by a management team with deep experience in biotechnology, regulatory affairs and commercialization. The company operates primarily in Canada and the United States, while seeking strategic alliances to extend its geographic reach and accelerate the clinical advancement of its product candidates.View Theratechnologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are Done Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
